$80,000 of QUEST DIAGNOSTICS INCORPORATED lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"H.R. 1 - One Big Beautiful Bill Act - Issues related to Medicaid and other provisions impacting access to laboratory services for covered populations. Policies, rules, and regulations related to clinical laboratories and Medicare coverage policies."
You can find more data on corporate lobbying on Quiver Quantitative.
DGX Insider Trading Activity
DGX insiders have traded $DGX stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $DGX stock by insiders over the last 6 months:
- MICHAEL E PREVOZNIK (SVP & General Counsel) has made 0 purchases and 4 sales selling 28,690 shares for an estimated $5,368,747.
- PATRICK PLEWMAN (SVP for Diagnostic Services) has made 0 purchases and 5 sales selling 14,017 shares for an estimated $2,518,856.
- KARTHIK KUPPUSAMY (SVP, Clinical Solutions) has made 0 purchases and 3 sales selling 10,479 shares for an estimated $1,759,930.
- MARK E DELANEY (SVP & Chief Commercial Officer) has made 0 purchases and 2 sales selling 1,748 shares for an estimated $306,800.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
DGX Hedge Fund Activity
We have seen 458 institutional investors add shares of DGX stock to their portfolio, and 414 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,210,459 shares (+20.2%) to their portfolio in Q2 2025, for an estimated $217,434,750
- DAVIS SELECTED ADVISERS removed 1,033,882 shares (-43.3%) from their portfolio in Q2 2025, for an estimated $185,716,223
- NORDEA INVESTMENT MANAGEMENT AB removed 1,029,219 shares (-81.9%) from their portfolio in Q2 2025, for an estimated $184,878,608
- M&G PLC added 771,824 shares (+256.5%) to their portfolio in Q2 2025, for an estimated $138,642,745
- BOSTON PARTNERS added 739,407 shares (+32.2%) to their portfolio in Q2 2025, for an estimated $132,819,679
- SQUAREPOINT OPS LLC added 688,297 shares (+444.1%) to their portfolio in Q2 2025, for an estimated $123,638,790
- JPMORGAN CHASE & CO added 561,722 shares (+14.9%) to their portfolio in Q2 2025, for an estimated $100,902,122
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
DGX Analyst Ratings
Wall Street analysts have issued reports on $DGX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Baird issued a "Outperform" rating on 04/23/2025
To track analyst ratings and price targets for DGX, check out Quiver Quantitative's $DGX forecast page.
DGX Price Targets
Multiple analysts have issued price targets for $DGX recently. We have seen 8 analysts offer price targets for $DGX in the last 6 months, with a median target of $190.0.
Here are some recent targets:
- Elizabeth Anderson from Evercore ISI Group set a target price of $190.0 on 10/08/2025
- Stephanie Davis from Barclays set a target price of $190.0 on 10/02/2025
- Eric Coldwell from Baird set a target price of $194.0 on 08/25/2025
- Kevin Caliendo from UBS set a target price of $180.0 on 07/23/2025
- David Macdonald from Truist Securities set a target price of $192.0 on 07/23/2025
- Pito Chickering from Deutsche Bank set a target price of $178.0 on 07/23/2025
- Lisa Gill from JP Morgan set a target price of $190.0 on 05/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
